Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.6373 per share.
- Transaction Volume: 54 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of 54 ordinary shares by Mr. D S Redfern, Chief Strategy Officer, on July 14, 2016. This acquisition resulted from the re-investment of dividends paid on July 14, 2016, under the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of an insider share transaction executed on the London Stock Exchange.
Investor Verification Points
- Verify the identity of the PDMR involved: Mr. D S Redfern, Chief Strategy Officer.
- Confirm the transaction nature: Acquisition via dividend re-investment under the ShareReward Plan.
- Note the transaction date (July 14, 2016) and execution venue (London Stock Exchange).
- Recognize that this filing does not contain quarterly or annual financial performance data.